PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia(TM) Sustained Drug Delivery Technology
By asianet
– Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically – Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma PolyActiva Pty Ltd ( https://c212.net/c/link/?t=0&l=en&o=3448237-1&h=1299399622&u=https%3A%2F%2Fpolyactiva.com%2F&a=PolyActiva+Pty+Ltd ), a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the … Continued